​READDI brings together partners from around the world to leverage their existing knowledge, platforms and relationships to accelerate innovation. Together, this unparalleled collaboration could make all the difference in the world.

Founding Partners

University of North Carolina (UNC)-Chapel Hill
UNC-Chapel Hill ranks 8th among more than 25,000 institutions worldwide in coronavirus research and 5th in the nation in federal research funding. The UNC School of Medicine brings more than two decades of virology expertise to the initiative. According to U.S. News & World Report, the UNC Eshelman School of Pharmacy, home to the Eshelman Institute for Innovation (EII), ranks first in the nation; the UNC Gillings School of Global Public Health ranks second. 

Structural Genomics Consortium (SGC)
The SGC is driving a new scientific and drug discovery ecosystem by focusing on less well-studied areas of the human genome. A pioneer of open science, the consortium's network of academic and industry scientists catalyzes research in new areas of human biology and drug discovery by focusing on genetics — and they share all research with the scientific community — no strings attached. The SGC has partnerships with nine global pharmaceutical companies and collaborations with scientists in hundreds of universities globally.

Advisors

Drugs for Neglected Diseases initiative (DNDi)
DNDi has provided READDI with a proven model, given their own approach for non-profit drug research. Founded by Médecins Sans Frontières (MSF), the World Health Organization and five international research institutions, DNDi discovers, develops and delivers new treatments for neglected patients around the world that are affordable and patient-friendly — and have already saved millions of lives.